Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient s...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2019-01, Vol.106, p.144-159 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 159 |
|---|---|
| container_issue | |
| container_start_page | 144 |
| container_title | European journal of cancer (1990) |
| container_volume | 106 |
| creator | Prelaj, Arsela Tay, Rebecca Ferrara, Roberto Chaput, Nathalie Besse, Benjamin Califano, Raffaele |
| description | Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.
•At present, tumour PD-L1 expression is the only approved biomarker, albeit imperfect, used in clinical practice for PD-(L)1 blockade in NSCLC.•Tumour Mutational Burden may enter clinical practice as a biomarker to select patients who are potential candidates for dual immune blockade.•Several biomarker strategies specifically related to NSCLC are under investigation.•Tumour-related factors such as genetic alterations and tumour microenvironment play a crucial role and are relevant for a prediction role.•Factors related to the host immune system (peripheral blood biomarkers etc.) and their combination with other biomarkers will be the next future. |
| doi_str_mv | 10.1016/j.ejca.2018.11.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2173762406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804918314552</els_id><sourcerecordid>2173762406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-4fbddd8aa836285ac689a9ed2072b91f7aaf9ae91877829e18974a663bab5de33</originalsourceid><addsrcrecordid>eNp9kM1O3TAQha0KVC7QF-iissQ66dj5s6VuKtQWJCRYwNpy7ElxSOyLnSB113foG_Ik-OoCy65m850zOh8hnxmUDFj7dSxxNLrkwETJWAnAP5ANE50sQDT8gGxANrIQUMsjcpzSCACdqOEjOaqg4ZmTG9LfRLTOLO4Jae_CrOMDxkTDQCOmbfAJ6RAidfO8eqTmHs3DNji_UOfvXe-WkGHnqQ_--e-_NOtpKgxOE51W_5sa7Q3GU3I46Cnhp9d7Qu5-_rg9vyiurn9dnn-_KkzdwFLUQ2-tFVqLquWi0aYVUku0HDreSzZ0Wg9So8wDO8ElMiG7Wrdt1eu-sVhVJ-Rs37uN4XHFtKgxrNHnl4qzrupaXkObKb6nTAwpRRzUNro8-49ioHZa1ah2WtVOq2JMZa059OW1eu1ntO-RN48Z-LYHMA98chhVMg7zeusimkXZ4P7X_wInT4s_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2173762406</pqid></control><display><type>article</type><title>Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Prelaj, Arsela ; Tay, Rebecca ; Ferrara, Roberto ; Chaput, Nathalie ; Besse, Benjamin ; Califano, Raffaele</creator><creatorcontrib>Prelaj, Arsela ; Tay, Rebecca ; Ferrara, Roberto ; Chaput, Nathalie ; Besse, Benjamin ; Califano, Raffaele</creatorcontrib><description>Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.
•At present, tumour PD-L1 expression is the only approved biomarker, albeit imperfect, used in clinical practice for PD-(L)1 blockade in NSCLC.•Tumour Mutational Burden may enter clinical practice as a biomarker to select patients who are potential candidates for dual immune blockade.•Several biomarker strategies specifically related to NSCLC are under investigation.•Tumour-related factors such as genetic alterations and tumour microenvironment play a crucial role and are relevant for a prediction role.•Factors related to the host immune system (peripheral blood biomarkers etc.) and their combination with other biomarkers will be the next future.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2018.11.002</identifier><identifier>PMID: 30528799</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anticancer properties ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - therapeutic use ; Apoptosis ; B7-H1 Antigen - antagonists & inhibitors ; B7-H1 Antigen - immunology ; Biomarkers ; Biomarkers, Tumor - antagonists & inhibitors ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - immunology ; Cancer ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - immunology ; Carcinoma, Non-Small-Cell Lung - mortality ; Humans ; Immune checkpoint ; Immune system ; Immunotherapy ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - immunology ; Lung Neoplasms - mortality ; Microsatellite instability ; Mutation ; Non-small cell lung carcinoma ; NSCLC ; PD-L1 ; Peripheral blood ; Predictive biomarkers ; Predictive Value of Tests ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - immunology ; Risk Assessment ; Risk Factors ; Signal Transduction ; Toxicity ; Transcriptome ; Treatment Outcome ; Tumor Microenvironment ; Tumors ; Tumour microenvironment ; Tumour mutational burden</subject><ispartof>European journal of cancer (1990), 2019-01, Vol.106, p.144-159</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Jan 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-4fbddd8aa836285ac689a9ed2072b91f7aaf9ae91877829e18974a663bab5de33</citedby><cites>FETCH-LOGICAL-c450t-4fbddd8aa836285ac689a9ed2072b91f7aaf9ae91877829e18974a663bab5de33</cites><orcidid>0000-0003-2611-5319</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2018.11.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30528799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prelaj, Arsela</creatorcontrib><creatorcontrib>Tay, Rebecca</creatorcontrib><creatorcontrib>Ferrara, Roberto</creatorcontrib><creatorcontrib>Chaput, Nathalie</creatorcontrib><creatorcontrib>Besse, Benjamin</creatorcontrib><creatorcontrib>Califano, Raffaele</creatorcontrib><title>Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.
•At present, tumour PD-L1 expression is the only approved biomarker, albeit imperfect, used in clinical practice for PD-(L)1 blockade in NSCLC.•Tumour Mutational Burden may enter clinical practice as a biomarker to select patients who are potential candidates for dual immune blockade.•Several biomarker strategies specifically related to NSCLC are under investigation.•Tumour-related factors such as genetic alterations and tumour microenvironment play a crucial role and are relevant for a prediction role.•Factors related to the host immune system (peripheral blood biomarkers etc.) and their combination with other biomarkers will be the next future.</description><subject>Anticancer properties</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Apoptosis</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>B7-H1 Antigen - immunology</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - antagonists & inhibitors</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - immunology</subject><subject>Cancer</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - immunology</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - mortality</subject><subject>Microsatellite instability</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>NSCLC</subject><subject>PD-L1</subject><subject>Peripheral blood</subject><subject>Predictive biomarkers</subject><subject>Predictive Value of Tests</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Signal Transduction</subject><subject>Toxicity</subject><subject>Transcriptome</subject><subject>Treatment Outcome</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><subject>Tumour microenvironment</subject><subject>Tumour mutational burden</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1O3TAQha0KVC7QF-iissQ66dj5s6VuKtQWJCRYwNpy7ElxSOyLnSB113foG_Ik-OoCy65m850zOh8hnxmUDFj7dSxxNLrkwETJWAnAP5ANE50sQDT8gGxANrIQUMsjcpzSCACdqOEjOaqg4ZmTG9LfRLTOLO4Jae_CrOMDxkTDQCOmbfAJ6RAidfO8eqTmHs3DNji_UOfvXe-WkGHnqQ_--e-_NOtpKgxOE51W_5sa7Q3GU3I46Cnhp9d7Qu5-_rg9vyiurn9dnn-_KkzdwFLUQ2-tFVqLquWi0aYVUku0HDreSzZ0Wg9So8wDO8ElMiG7Wrdt1eu-sVhVJ-Rs37uN4XHFtKgxrNHnl4qzrupaXkObKb6nTAwpRRzUNro8-49ioHZa1ah2WtVOq2JMZa059OW1eu1ntO-RN48Z-LYHMA98chhVMg7zeusimkXZ4P7X_wInT4s_</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Prelaj, Arsela</creator><creator>Tay, Rebecca</creator><creator>Ferrara, Roberto</creator><creator>Chaput, Nathalie</creator><creator>Besse, Benjamin</creator><creator>Califano, Raffaele</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0003-2611-5319</orcidid></search><sort><creationdate>201901</creationdate><title>Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer</title><author>Prelaj, Arsela ; Tay, Rebecca ; Ferrara, Roberto ; Chaput, Nathalie ; Besse, Benjamin ; Califano, Raffaele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-4fbddd8aa836285ac689a9ed2072b91f7aaf9ae91877829e18974a663bab5de33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anticancer properties</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Apoptosis</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>B7-H1 Antigen - immunology</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - antagonists & inhibitors</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - immunology</topic><topic>Cancer</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - immunology</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - mortality</topic><topic>Microsatellite instability</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>NSCLC</topic><topic>PD-L1</topic><topic>Peripheral blood</topic><topic>Predictive biomarkers</topic><topic>Predictive Value of Tests</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Signal Transduction</topic><topic>Toxicity</topic><topic>Transcriptome</topic><topic>Treatment Outcome</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><topic>Tumour microenvironment</topic><topic>Tumour mutational burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prelaj, Arsela</creatorcontrib><creatorcontrib>Tay, Rebecca</creatorcontrib><creatorcontrib>Ferrara, Roberto</creatorcontrib><creatorcontrib>Chaput, Nathalie</creatorcontrib><creatorcontrib>Besse, Benjamin</creatorcontrib><creatorcontrib>Califano, Raffaele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prelaj, Arsela</au><au>Tay, Rebecca</au><au>Ferrara, Roberto</au><au>Chaput, Nathalie</au><au>Besse, Benjamin</au><au>Califano, Raffaele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2019-01</date><risdate>2019</risdate><volume>106</volume><spage>144</spage><epage>159</epage><pages>144-159</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.
•At present, tumour PD-L1 expression is the only approved biomarker, albeit imperfect, used in clinical practice for PD-(L)1 blockade in NSCLC.•Tumour Mutational Burden may enter clinical practice as a biomarker to select patients who are potential candidates for dual immune blockade.•Several biomarker strategies specifically related to NSCLC are under investigation.•Tumour-related factors such as genetic alterations and tumour microenvironment play a crucial role and are relevant for a prediction role.•Factors related to the host immune system (peripheral blood biomarkers etc.) and their combination with other biomarkers will be the next future.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30528799</pmid><doi>10.1016/j.ejca.2018.11.002</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-2611-5319</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2019-01, Vol.106, p.144-159 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_journals_2173762406 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anticancer properties Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Apoptosis B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - immunology Biomarkers Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - genetics Biomarkers, Tumor - immunology Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - mortality Humans Immune checkpoint Immune system Immunotherapy Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - immunology Lung Neoplasms - mortality Microsatellite instability Mutation Non-small cell lung carcinoma NSCLC PD-L1 Peripheral blood Predictive biomarkers Predictive Value of Tests Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology Risk Assessment Risk Factors Signal Transduction Toxicity Transcriptome Treatment Outcome Tumor Microenvironment Tumors Tumour microenvironment Tumour mutational burden |
| title | Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A31%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20biomarkers%20of%20response%20for%20immune%20checkpoint%20inhibitors%20in%20non%E2%80%93small-cell%20lung%20cancer&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Prelaj,%20Arsela&rft.date=2019-01&rft.volume=106&rft.spage=144&rft.epage=159&rft.pages=144-159&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2018.11.002&rft_dat=%3Cproquest_cross%3E2173762406%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2173762406&rft_id=info:pmid/30528799&rft_els_id=S0959804918314552&rfr_iscdi=true |